Myoglobin as a Marker for Rhabdomyosarcomas
Author Information
Author(s): M. Leader, J. Patel, M. Collins, K. Henry
Primary Institution: Charing Cross and Westminster Medical School
Hypothesis
This study aimed to evaluate the sensitivity and specificity of myoglobin antiserum as a marker for rhabdomyosarcomas.
Conclusion
Myoglobin is a specific but not very sensitive marker for rhabdomyosarcomas, showing positive staining in 60% of cases.
Supporting Evidence
- 60% of rhabdomyosarcomas stained positively with the myoglobin antiserum.
- Only 0.88% of non-skeletal muscle tumours showed a positive reaction.
- The study confirmed the histopathological diagnosis of all rhabdomyosarcomas tested.
Takeaway
This study looked at how well a special test can find a type of cancer called rhabdomyosarcoma, and it found that the test works well but not perfectly.
Methodology
The study involved testing 183 soft tissue sarcomas, including 25 rhabdomyosarcomas, with a polyclonal anti-human myoglobin antiserum to assess staining results.
Potential Biases
Potential misinterpretation of staining results due to the presence of residual myocytes and the effects of prior radiotherapy on staining.
Limitations
The sensitivity of the myoglobin marker varied and was dependent on the source of the antibody used.
Participant Demographics
The study included a variety of soft tissue sarcomas from a pathology department over a 20-year period.
Want to read the original?
Access the complete publication on the publisher's website